Sequenom Shares Slide on Nasdaq Delisting Warning

genomeweb
360dx

Sequenom Shares Slide on Nasdaq Delisting Warning

Sep 20, 2005

NEW YORK, Sept. 20 (GenomeWeb News) - Shares of Sequenom's stock are down 4.88 percent, or $.04, at $.78 today following news this morning that the company has received a delisting warning letter from the Nasdaq exchange.

To read the full story....

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

NuGen, KeyGene Settle Patent Infringement Dispute
Top Five Articles on GenomeWeb Last Week: Illumina, Flatiron, PapGene, and More
Lucence Dx Signs Philippine Distribution Deal for Cancer Tests
UCSD Researchers Establish Mutational Landscape of Appendiceal Cancer
People in the News: Hal Barron, Hans Bishop, Mitchell Nelles, Albert Parker
In Brief This Week: Agilent, Co-Diagnostics, Bio-Techne, and More

The Scan

An RNAi Approval

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Stop It There

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

Keep It Going

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

This Week in PLOS

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.

Main menu